Clinical trials: CGM
Diabetes Mellitus, Continuous Glucose Monitoring System
To Evaluate the Change in Glucose Parameters in Adult Patients With Type 1 or Type 2 Diabetes From Europe Using the iCan o3 CGM System for 60 Days Period
This study is a post-market, prospective, interventional, multicenter clinical trial designed to evaluate the impact of the iCan O3 Continuous Glucose Monitoring (CGM) System on glycemic control in adults with Type 1 (T1D) or…
- Trial name
- DETECT (NCT06904846)
- Testing
- iCan o3 CGM Continuous Glucose Monitoring System
- Where
- Belgium
- Volunteers
- 70 people
- Sponsor
- Sinocare
Diabetes Mellitus, Type 2
An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin
The main purpose of this study is to assess the effects of 4 weeks each of daily treatment with canagliflozin 300 milligram (mg) versus sitagliptin 100 mg as treatment adjuncts to metformin (at stable dosages) on intrapatient…
- Trial name
- COMETA (NCT03267576)
- Testing
- Canagliflozin 300 mg, Sitagliptin 100 mg, Metformin
- Where
- 5 sites in Mexico
- Volunteers
- 64 people
- Sponsor
- Janssen Research & Development, LLC
Type 2 Diabetes Mellitus
Glycemic Holter Study (Continuous Glucose Monitoring) -
The study will assess glycemic variability and optimized glycemic control in T2DM patients treated with a DPP-4 inhibitor as add-on therapy to metformin.
- Trial name
- OPTIMA (NCT01193296)
- Testing
- Vildagliptin, Sitagliptin
- Where
- 7 sites in France
- Volunteers
- 36 people
- Sponsor
- Novartis
Stress Urinary Incontinence (SUI)
Stress Urinary Incontinence for Female Patients (CGM MUIT-2301)
This study is a multicenter, prospective, randomized, double-blind, sham-controlled clinical trial conducted in female patients with stress urinary incontinence.
- Trial name
- NCT07440927
- Testing
- Ceragem Innerfit medi-tech
- Where
- South Korea
- Volunteers
- 96 people
- Sponsor
- Ceragem Clinical Inc.
Diabetes
A Comparison Study of Prototype Continuous Glucose Sensors in the Intradermal and Subcutaneous Spaces
The purpose of this study is to compare two continuous glucose sensors, one placed subcutaneous (under the skin) and one placed intradermal (in the skin) over 12-14 hours.
- Trial name
- NCT01093833
- Testing
- BD Continuous glucose monitor (BD CGM), YSI Glucose Analyzer, Medtronic Guardian CGM
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Becton, Dickinson and Company
Type 1 Diabetes Mellitus
Effectiveness Study of the Guardian RT in Type 1 Diabetics
The purpose of this study is to determine whether Type 1 diabetic patients using the Guardian RT glucose sensor can improve glycemic control over a 12-week period, compared to patients using self-monitoring blood glucose testing…
- Trial name
- NCT01331343
- Testing
- Guardian RT Telemetered Glucose Monitoring System
- Where
- 8 sites in France, Germany and 5 more
- Volunteers
- 156 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Diabetes Mellitus, Type 1
Post Approval Study of the Eversense® Continuous Glucose Monitoring
A Post Approval Study to Evaluate the Long-term Safety and Effectiveness of the Eversense® Continuous Glucose Monitoring (CGM) System over repeat insertion and removal cycles and to demonstrate the long-term safety of the…
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- PAS (NCT03908125)
- Testing
- Eversense® CGM System
- Where
- 17 sites in United States
- Volunteers
- 273 people
- Sponsor
- Senseonics, Inc.
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Clinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range Compared With Self-Monitoring of Blood Glucose in Participants With Type 1 and Type 2 Diabetes Mellitus
This is an open label, two-arm, randomized multi-center clinical device study in adult subjects with Type 1 diabetes (T1D) or insulin-dependent Type 2 diabetes (T2D) on a multiple daily injection (MDI) regime.
- Trial name
- NCT06704672
- Testing
- Accu-Chek SmartGuide CGM Solution, Accu-Chek SmartGuide Sensor and Blinded Apps, SMBG Device
- Where
- 20 sites in Poland, Turkey (Türkiye)
- Volunteers
- 270 people
- Sponsor
- Hoffmann-La Roche
T1D, Type 1 Diabetes (T1D)
Evaluation of a Biopsychosocial System
The goal of this observational study is to evaluate the feasibility of a biopsychosocial sensing system integrated into the Adhera Caring Digital Program® for caregivers of children with type 1 diabetes (T1D).
- Conditions
- T1D, Type 1 Diabetes (T1D), Type 1 Diabetes
- Trial name
- NCT07440108
- Testing
- Use of Biopsychosocial Sensing System
- Where
- Spain
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Adhera Health, Inc.
Glucose Metabolism Disorders
Continuous Glucose Monitoring During Diets That Differ in Glycemic Load
This study test whether a Continuous Glucose Monitor can pickup differences in glucose (in the interstitial fluid) during a dietary intervention using meals with either a high with a low glycemic load.
- Trial name
- GLOW (NCT02926118)
- Testing
- Low glycemic load, High glycemic load
- Where
- Netherlands
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Unilever R&D
Diabetes Mellitus
Effectiveness and Safety of the RIGHTEST™ CGM System for Blood Glucose Management in Persons With Diabetes Mellitus
The trial is expected to enroll 50 confirmed cases of type 1 or type 2 diabetes. All eligible subjects must wear a continuous glucose monitoring system on both the left and right upper arms for a maximum of 15 days (360 hours)…
- Trial name
- NCT07888582
- Testing
- RIGHTEST Continuous Glucose Monitoring System
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Bionime Corporation
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Effectiveness and Safety Study of the Next-Generation DexCom™ SEVEN® Continuous Glucose Monitoring System
The purpose of this study is to evaluate the safety and effectiveness of the next-generation DexCom SEVEN Continuous Glucose Monitoring System (SEVEN.2 System) when worn for up to 7-days by subjects >18 years-old with diabetes…
- Trial name
- NCT00722241
- Where
- 3 sites in United States
- Volunteers
- 53 people
- Sponsor
- DexCom, Inc.
Weight Loss, Metabolic Syndrome
Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)
The use of continuous glucose monitoring (CGM) in earlier data has inspired behavioral changes leading to improved adherence to an exercise plan in individuals and eating habits in people with diabetes.
- Conditions
- Weight Loss, Metabolic Syndrome, Diabetes Mellitus, Type 2, Central Obesity
- Trial name
- NCT05874635
- Testing
- Continuous Glucose Monitor Device
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Signos Inc
Type 2 Diabetes Treated With Insulin
Initiation of Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin, in Italy
The goal of this clinical study is to determine the impact of starting the use of the FreeStyle Libre 2 glucose monitoring system, over a three month period, on HbA1c in adults with type 2 diabetes treated with a basal insulin…
- Trial name
- NCT06268808
- Testing
- FreeStyle Libre 2 Flash Glucose Monitoring System
- Where
- 8 sites in Italy
- Volunteers
- 90 people
- Sponsor
- Abbott Diabetes Care
T1DM - Type 1 Diabetes Mellitus
The True Vie I3 Continuous Glucose Monitoring System in Pediatric Patients With Type 1 Diabetes Mellitus
The purpose of the investigation is to evaluate the performance of the I3 CGM in Pediatric Patients with Type 1 Diabetes Mellitus (T1DM) according to the FDA's special controls for iCGM.
- Trial name
- NCT05908448
- Testing
- 13 CGM (continuous glucose monitor)
- Where
- United States
- Volunteers
- 134 people
- Sponsor
- Sinocare
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Metronom Continuous Glucose Monitoring System
The aim of the present study is to investigate the clinical performance of the Metronom CGM system in patients with type 1 diabetes over a period of 14 days.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabete Mellitus
- Trial name
- NCT03341026
- Testing
- Metronom CGM device
- Where
- 2 sites in Austria, Denmark
- Volunteers
- 20 people
- Sponsor
- Metronom Health
Diabetes Mellitus
Performance of the Dexcom Continuous Glucose Monitoring (CGM) System in Pregnant Women With Diabetes Mellitus
Performance of the Dexcom Continuous Glucose Monitoring (CGM) System in Pregnant Women With Diabetes Mellitus
- Trial name
- NCT04905628
- Testing
- Dexcom CGM System
- Where
- 5 sites in United States
- Volunteers
- 100 people
- Sponsor
- DexCom, Inc.
Type 1 Diabetes
Use of the Paradigm 722 System to Improve Glycemic Control in Adult and Adolescent Subjects With Type 1 Diabetes
The purpose of this study is to determine whether Type 1 Diabetic subjects using the Paradigm 722 System, which is a glucose sensor-augmented insulin pump, can improve glycemic control when compared to subjects using the Paradigm…
- Trial name
- STAR1 (NCT00211510)
- Testing
- Paradigm 722 sensor augmented pump, Paradigm 715 insulin pump
- Where
- 7 sites in United States
- Volunteers
- 146 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus
Use of Mellitor Sensor for Continuous Glucose Monitoring - An Ex-Vivo Study
Most patients with diabetes mellitus have to measure their blood glucose levels quite often, in order to maintain a proper glycemic control.
- Trial name
- NCT00746642
- Testing
- Mellitor device for glucose measurement
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Mellitor
Diabetes Mellitus
Evaluation of the Safety and Effectiveness of the Dexcom Continuous Glucose Monitoring (CGM) System
Evaluation of the Safety and Effectiveness of the Dexcom Glucose Monitoring (CGM) System
- Trial name
- NCT04794478
- Testing
- Dexcom Continuous Glucose Monitoring System
- Where
- 12 sites in United States
- Volunteers
- 482 people
- Sponsor
- DexCom, Inc.